Physician profile
Orlando E Rodriguez
NPI 1346353190
$3,758.06
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $2,192 · 2021: $331 · 2022: $278 · 2023: $418 · 2024: $4.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413 · Education: $10.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.57 |
| Education | $10.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,339.23 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $226.84 | 2021-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $172.83 | 2019-2023 | Jynarque |
| Amgen INC. | $170.20 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $146.07 | 2021-2023 | Lupkynis |
| Lundbeck LLC | $133.04 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $102.28 | 2020-2023 | Acthar |
| Travere Therapeutics, INC. | $63.86 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.12 | 2021-2023 | |
| Genentech USA, INC. | $42.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $40.15 | 2021 | |
| Mallinckrodt Enterprises LLC | $38.60 | 2019 | |
| Vifor Pharma, INC. | $36.64 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $35.83 | 2019 | |
| Merck Sharp & Dohme LLC | $32.46 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29.21 | 2019-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2023 | Gattex |
| Philips North America LLC | $16.57 | 2023 | |
| Akebia Therapeutics INC | $15.35 | 2019 | |
| Amarin Pharma, INC. | $14.83 | 2020 | |
| Calliditas Therapeutics US INC. | $14.05 | 2022 | |
| Glaxosmithkline, LLC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlando Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.